Inomata M - Search Results

1

Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042).

Minegishi Y, Akagami T, Arai M, Saito R, Arai D, Murase K, Miura K, Watanabe S, Sakashita H, Miyabayashi T, Honda R, Jingu D, Hotta T, Isobe K, Nakazawa K, Ito K, Takamura K, Inomata M, Harada T, Sakakibara R, Nakagawa T, Shibuya H, Takenaka K, Kobayashi K, Seike M. Minegishi Y, et al. Among authors: inomata m. Lung Cancer. 2022 Oct;172:1-8. doi: 10.1016/j.lungcan.2022.07.009. Epub 2022 Jul 26. Lung Cancer. 2022. PMID: 35952438 Review.

2

[Efficacy and toxicity of pemetrexed monotherapy for previously untreated elderly patients with non-squamous cell lung cancer with wild-type(or unknown)EGFR status].

Inomata M, Hayashi R, Tokui K, Okazawa S, Taka C, Kambara K, Suzuki K, Yamada T, Miwa T, Matsui S, Kashii T, Tobe K. Inomata M, et al. Gan To Kagaku Ryoho. 2014 Jul;41(7):849-52. Gan To Kagaku Ryoho. 2014. PMID: 25131870 Japanese.

3

Utility of creatinine/cystatin C ratio as a predictive marker for adverse effects of chemotherapy in lung cancer: A retrospective study.

Suzuki K, Furuse H, Tsuda T, Masaki Y, Okazawa S, Kambara K, Inomata M, Miwa T, Matsui S, Kashii T, Taniguchi H, Hayashi R, Tobe K. Suzuki K, et al. Among authors: inomata m. J Int Med Res. 2015 Aug;43(4):573-82. doi: 10.1177/0300060515579116. Epub 2015 May 29. J Int Med Res. 2015. PMID: 26024878 Free article.

4

Lactate dehydrogenase and body mass index are prognostic factors in patients with recurrent small cell lung cancer receiving amrubicin.

Inomata M, Hayashi R, Tokui K, Taka C, Okazawa S, Kambara K, Ichikawa T, Yamada T, Miwa T, Kashii T, Matsui S, Tobe K. Inomata M, et al. Tumori. 2016 Dec 1;102(6):606-609. doi: 10.5301/tj.5000435. Epub 2015 Sep 30. Tumori. 2016. PMID: 26429641

5

Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer.

Inomata M, Shimokawa K, Tokui K, Taka C, Okazawa S, Kambara K, Yamada T, Miwa T, Hayashi R, Kashii T, Matsui S, Tobe K. Inomata M, et al. Anticancer Res. 2016 Sep;36(9):4951-4. doi: 10.21873/anticanres.11062. Anticancer Res. 2016. PMID: 27630354

6

[A Retrospective Study Analyzing the Clinical Course of Patients with Non-Small Cell Lung Cancer Receiving Local or Systemic Therapy after Post-Operative Recurrence].

Inomata M, Tanaka H, Shimokawa K, Tokui K, Okazawa S, Taka C, Kambara K, Imanishi S, Yamada T, Miwa T, Hayashi R, Matsui S, Kashii T, Homma T, Nomura K, Doki Y, Tobe K. Inomata M, et al. Gan To Kagaku Ryoho. 2017 Sep;44(9):767-770. Gan To Kagaku Ryoho. 2017. PMID: 28912406 Japanese.

7

Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer.

Seto Z, Takata N, Murayama N, Tokui K, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Inomata M. Seto Z, et al. Among authors: inomata m. Tumori. 2021 Dec;107(6):536-541. doi: 10.1177/0300891620974762. Epub 2020 Nov 25. Tumori. 2021. PMID: 34847814

8

Small cell lung cancer; recent advances of its biology and therapeutic perspective.

Hayashi R, Inomata M. Hayashi R, et al. Among authors: inomata m. Respir Investig. 2022 Mar;60(2):197-204. doi: 10.1016/j.resinv.2021.10.008. Epub 2021 Dec 10. Respir Investig. 2022. PMID: 34896039 Review.

9

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data.

Terai H, Soejima K, Shimokawa A, Horinouchi H, Shimizu J, Hase T, Kanemaru R, Watanabe K, Ninomiya K, Aragane N, Yanagitani N, Sakata Y, Seike M, Fujimoto D, Kasajima M, Kubo A, Kusumoto S, Oyamada Y, Fujiwara K, Mori M, Hashimoto M, Shingyoji M, Kodani M, Sakamoto J, Agatsuma T, Kashiwabara K, Inomata M, Tachihara M, Tanaka K, Hayashihara K, Koyama N, Matsui K, Minato K, Jingu D, Sakashita H, Hara S, Naito T, Okada A, Tanahashi M, Sato Y, Asano K, Takeda T, Nakazawa K, Harada T, Shibata K, Kato T, Miyaoka E, Yoshino I, Gemma A, Mitsudomi T. Terai H, et al. Among authors: inomata m. JTO Clin Res Rep. 2022 Sep 1;3(11):100404. doi: 10.1016/j.jtocrr.2022.100404. eCollection 2022 Nov. JTO Clin Res Rep. 2022. PMID: 36275911 Free PMC article.

10

Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.

Inomata M, Matsumoto M, Hayashi K, Seto Z, Hirai T, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Tobe K. Inomata M, et al. Anticancer Res. 2023 Jul;43(7):3241-3246. doi: 10.21873/anticanres.16498. Anticancer Res. 2023. PMID: 37351972

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

695 results

Search Page

Filters